{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:52:48Z","timestamp":1783468368365,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaip.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T13:40:50Z","timestamp":1644932450000},"page":"1131-1138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diagnosis and Management of Pediatric Hypereosinophilic Syndrome"],"prefix":"10.1016","volume":"10","author":[{"given":"Chen E.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C.","family":"Fulkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli W.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.02.007_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.02.007_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2257.2000.00288.x","article-title":"Total and differential leucocyte counts in infants at 2, 5 and 13 months of age","volume":"22","author":"Bellamy","year":"2000","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2257.1997.00204.x","article-title":"Haematological reference ranges for schoolchildren","volume":"19","author":"Taylor","year":"1997","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization\u2013defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.02.007_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaip.2016.03.020","article-title":"Hypereosinophilia in children and adults: a retrospective comparison","volume":"4","author":"Williams","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib8","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes\u2014an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaip.2022.02.007_bib9","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","article-title":"De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases","volume":"46","author":"Aksentijevich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2022.02.007_bib10","first-page":"903","article-title":"Prevalence of atopic features in classic autoinflammatory diseases [abstract]","volume":"71","author":"Dizon","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2022.02.007_bib11","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.jaip.2019.05.011","article-title":"Pediatric hypereosinophilia: characteristics, clinical manifestations, and diagnoses","volume":"7","author":"Burris","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ajh.23515","article-title":"Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death","volume":"88","author":"Andersen","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib13","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood-2012-07-443424","article-title":"Use of 111-indium-labeled autologous eosinophils to establish the in\u00a0vivo kinetics of human eosinophils in healthy subjects","volume":"120","author":"Farahi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.02.007_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fmed.2017.00075","article-title":"Eosinophil activation status in separate compartments and association with asthma","volume":"4","author":"Johansson","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2022.02.007_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaip.2022.02.007_bib16","doi-asserted-by":"crossref","first-page":"16418","DOI":"10.1073\/pnas.0607863103","article-title":"A\u00a0central regulatory role for eosinophils and the eotaxin\/CCR3 axis in chronic experimental allergic airway inflammation","volume":"103","author":"Fulkerson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.02.007_bib17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2353\/ajpath.2006.060617","article-title":"Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling","volume":"169","author":"Fulkerson","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2022.02.007_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.02.007_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaci.2018.05.003","article-title":"Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness","volume":"143","author":"Grozdanovic","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib20","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.4049\/jimmunol.148.11.3543","article-title":"Apoptosis in human eosinophils\u2014programmed cell-death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5","volume":"148","author":"Stern","year":"1992","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","article-title":"Biologic therapies targeting eosinophils: current status and future prospects","volume":"3","author":"Legrand","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.02.007_bib23","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib24","first-page":"618","article-title":"Eosinophil viability-enhancing activity in sputum from patients with bronchial asthma: contributions of interleukin-5 and granulocyte\/macrophage colony-stimulating factor","volume":"151","author":"Adachi","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.02.007_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1165\/ajrcmb.12.5.7742019","article-title":"Peripheral blood CD4 but not CD8 T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy","volume":"12","author":"Corrigan","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2022.02.007_bib26","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2003-11-3850","article-title":"Familial eosinophilia: a benign disorder?","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.02.007_bib27","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.4049\/jimmunol.0900634","article-title":"Human airway eosinophils respond to chemoattractants with greater eosinophil-derived neurotoxin release, adherence to fibronectin, and activation of the Ras-ERK pathway when compared with blood eosinophils","volume":"184","author":"Bates","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib28","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.4049\/jimmunol.149.11.3710","article-title":"Comparison of airway and blood eosinophil function after in\u00a0vivo antigen challenge","volume":"149","author":"Sedgwick","year":"1992","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib29","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2022.02.007_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fimmu.2014.00570","article-title":"Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity","volume":"5","author":"Davoine","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2014.00496","article-title":"Eosinophil secretion of granule-derived cytokines","volume":"5","author":"Spencer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nri3341-c1","article-title":"Primary lysis of eosinophils as a major mode of activation of eosinophils in human diseased tissues","volume":"13","author":"Persson","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.coi.2009.07.011","article-title":"Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology","volume":"21","author":"Neves","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib34","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1096\/fj.11-200246","article-title":"CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules","volume":"26","author":"Shamri","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.jaip.2022.02.007_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2022.02.007_bib36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11882-016-0634-5","article-title":"Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation","volume":"16","author":"Ueki","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2022.02.007_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nm.1855","article-title":"Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense","volume":"14","author":"Yousefi","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.02.007_bib38","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaip.2018.04.030","article-title":"Consultation for elevated blood eosinophils: clinical presentations, high value diagnostic tests, and treatment options","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fmed.2017.00240","article-title":"Clinical and biological markers in hypereosinophilic syndromes","volume":"4","author":"Khoury","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2022.02.007_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib41","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.02.007_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.2010.08394.x","article-title":"Molecular characterization of paediatric idiopathic hypereosinophilia","volume":"151","author":"Rapanotti","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/pai.13173","article-title":"Episodic angioedema with eosinophilia (Gleich syndrome) in children: a clinical review","volume":"31","author":"Bertrand","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib45","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJM198406213102501","article-title":"Episodic angioedema associated with eosinophilia","volume":"310","author":"Gleich","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.007_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3324\/haematol.2013.091264","article-title":"Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder","volume":"100","author":"Khoury","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2022.02.007_bib47","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.jaip.2020.04.025","article-title":"Single-organ and multisystem hypereosinophilic syndrome patients with gastrointestinal manifestations share common characteristics","volume":"8","author":"Kuang","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/pde.14144","article-title":"Cutaneous manifestations of childhood eosinophilic granulomatosis with polyangiitis (cEGPA): a case-based review","volume":"37","author":"Bridges","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.02.007_bib49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.iac.2015.05.004","article-title":"Eosinophilia associated with disorders of immune deficiency or immune dysregulation","volume":"35","author":"Williams","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.02.007_bib50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ejh.13437","article-title":"Causes of hypereosinophilia in 100 consecutive patients","volume":"105","author":"Moller","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2022.02.007_bib51","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/all.13146","article-title":"Dysregulation of interleukin 5 expression in familial eosinophilia","volume":"72","author":"Prakash Babu","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.02.007_bib52","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib53","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.02.007_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.007_bib55","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.007_bib56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2020.08.034","article-title":"Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient","volume":"9","author":"Forero Molina","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.007_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.02.007_bib58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:32:45Z","timestamp":1761975165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2213219822001349"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Pediatric Hypereosinophilic Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}